Aspc 1

Manufactured by American Type Culture Collection

Sourced in United States, Japan, China, Germany, United Kingdom, Italy

AsPC-1 is a cell line derived from a human pancreatic adenocarcinoma. It is a commonly used in vitro model for pancreatic cancer research.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

AsPC-1 cells AsPC‐1 and BxPC‐3 ASPC-1 cell line AsPC-1 pancreatic cancer cell line

793 protocols using aspc 1

Culturing Pancreatic Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

The five human pancreatic cancer cell lines Panc1, MIA PaCa-2, BxPC-3, AsPC-1 and SW1990 were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Panc1 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, ATCC) supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) penicillin/streptomycin (pen/strep). MIAPaCa-2 cells were kept in DMEM (ATCC) supplemented with 10% (v/v) FBS, 2.5% (v/v) horse serum, and 1% (v/v) pen/strep. BxPC-3, AsPC-1 and SW1990 were maintained in RPMI 1640 medium (ATCC) containing 10% (v/v) FBS and 1% (v/v) pen/strep. The additional three primary pancreatic cancer cell lines PaCaDD135, PaCaDD159 and PaCaDD185 were kindly provided by Dr. Felix Rueckert (Surgical Clinic Mannheim, University of Heidelberg, Mannheim, Germany). Culture medium for primary pancreatic cancer cells lines was assembled by mixing two parts of DMEM medium supplemented with 20% (v/v) FBS with one part of Keratinocyte-SFM. All cell lines were incubated at 37 °C in 5% CO₂.

Grimmig T., Moench R., Kreckel J., Haack S., Rueckert F., Rehder R., Tripathi S., Ribas C., Chandraker A., Germer C.T., Gasser M, & Waaga-Gasser A.M. (2016). Toll Like Receptor 2, 4, and 9 Signaling Promotes Autoregulative Tumor Cell Growth and VEGF/PDGF Expression in Human Pancreatic Cancer. International Journal of Molecular Sciences, 17(12), 2060.

+ Open protocol

+ Expand

Culturing Pancreatic Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human pancreatic cancer cell lines PANC-1 (CRL-1469), AsPC-1 (CRL-1682), BxPC-3 (CRL-1687) and MIA PaCa-2 (CRL-1420) cell lines were obtained from ATCC (Manassas, VA), grown, aliquotted and maintained in liquid nitrogen. Aliquots of AsPC-1, PANC-1, and BxPC-3 were thawed and grown in RPMI-1640 (ATCC, Manassas, VA) supplemented with 10% Fetal Bovine Serum (Hyclone, Logan, UT), 0.11mg/ml Sodium Pyruvate, 4.5g/L D-glucose, 18mM HEPES Buffer, 100U/mL penicillin G sodium, 100μg/ml streptomycin sulfate, 0.25μg/ml amphotericin B, 2mM L-glutamine and 50μg/mL gentamicin (Complete RPMI). Sodium pyruvate and glucose were purchased from Sigma, St Louis, MO. All other supplements were purchased from Gibco, Carlsbad, CA. The MIA PaCa-2 cell line was grown in DMEM media (ATCC, Manassas, VA) supplemented with 5% horse sera (ATCC, Manassas, VA), 10% Fetal Bovine Serum (Hyclone, Logan, UT), 100U/ml penicillin G sodium, 100μg/ml streptomycin sulfate, 0.25μg/ml amphotericin B and 50μg/mL gentamicin. Cells were maintained in a humidified incubator at 37°C and 5% CO₂.

Guzmán E.A., Maers K., Roberts J., Kemami-Wangun H.V., Harmody D, & Wright A.E. (2014). The Marine Natural Product Microsclerodermin A is a Novel Inhibitor of the Nuclear Factor Kappa B and Induces Apoptosis in Pancreatic Cancer Cells. Investigational new drugs, 33(1), 86-94.

+ Open protocol

+ Expand

KRAS-Mutant Pancreatic Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human PDAC cell lines (KRAS^G12D: PANC-1, AsPC-1; KRAS^G12V: Capan-2; KRAS^G12C: Mia-PaCa2; KRAS^WT: BxPC-3) were obtained from American Type Culture Collection (ATCC). HPDE cells were obtained from Binsui Biotechnology. The HLECs were obtained from ScienCell Research Laboratories. The PANC-1 (ATCC, CRL-1469MET; RRID: CVCL_A4BT) and Capan-2 cells (ATCC, HTB-80; RRID: CVCL_0026) were maintained in DMEM (Invitrogen) containing 10% FBS. The AsPC-1 (ATCC, CRL-1682; RRID: CVCL_0152), BxPC-3 (ATCC, CRL-1687; RRID: CVCL_0186), Mia-PaCa2 (ATCC, CRM-CRL-1420; RRID: CVCL_0428), and HPDE cells (ATCC, HTX1979C) were maintained in RPMI 1640 medium (Invitrogen) containing 10% FBS. The HLECs (ScienCell Research Laboratories, 2500) were maintained in endothelial cell medium (ScienCell Research Laboratories) supplemented with 5% FBS. All cells were cultured at 37°C in humidified air with 5% CO₂.

Luo Y., Li Z., Kong Y., He W., Zheng H., An M., Lin Y., Zhang D., Yang J., Zhao Y., Chen C, & Chen R. (2022). KRAS mutant–driven SUMOylation controls extracellular vesicle transmission to trigger lymphangiogenesis in pancreatic cancer. The Journal of Clinical Investigation, 132(14), e157644.

+ Open protocol

+ Expand

Culturing Pancreatic Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human pancreatic tumor cell lines (BxPC-3, AsPC-1, and Panc-1) were purchased from American Type Culture Collection (ATCC, VA, USA). BxPC-3 and AsPC-1 were maintained in Roswell Park Memorial Institute medium (RPMI)-1640 with L-glutamine and Phenol Red (ATCC) containing 10% (v/v) fetal bovine serum (Gibco, NY, USA) and antibiotics (50units/ml penicillin and 50μg/ml streptomycin) (ATCC). Panc-1 was maintained in Minimum Essential Medium (MEM) containing 10% (v/v) fetal bovine serum and antibiotics (50units/ml penicillin and 50μg/ml streptomycin). The cells were cultured in a humidified 5% (v/v) CO₂ air incubator at 37 °C. All pancreatic cancer cells used in the adhesion assay were from passages 2–6.

Suntravat M., Barret H.S., Jurica C.A., Lucena S.E., Perez J.C, & Sánchez E.E. (2015). Recombinant disintegrin (r-Cam-dis) from Crotalus adamanteus inhibits adhesion of human pancreatic cancer cell lines to laminin-1 and vitronectin. Journal of Venom Research, 6, 1-10.

+ Open protocol

+ Expand

Pancreatic Cancer Cell Line Characterization

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human pancreatic adenocarcinoma cell lines PANC-1, MiaPaCa-2, AsPC-1, BxPC-3, and PA-TU-8902 were purchased from the American Type Culture Collection. The pancreatic cancer cell line MDA Panc-28 was a gift from Dr. Paul J. Chiao (The University of Texas MD Anderson Cancer Center, Houston, TX). The human pancreatic adenocarcinoma cell line FG was obtained from Michael P. Vezeridis (The Warren Alpert Medical School of Brown University, Providence, RI) (16 (link)). The human metastatic pancreatic adenocarcinoma cell line COLO357 and its fast-growing liver-metastatic variant in nude mice, L3.7, were described previously (12 (link)). All of these cell lines were maintained in plastic flasks as adherent monolayers in Eagle's minimal essential medium supplemented with 10% fetal bovine serum (FBS), sodium pyruvate, nonessential amino acids, L-glutamine, and a vitamin solution (Flow Laboratories). PANC-1, MiaPaCa-2, AsPC-1, BxPC-3, and PA-TU-8902 were characterized or authenticated by the American Type Culture Collection using short tandem repeat profiling and passaged in our laboratory for fewer than 6 months after receipt. A competitive LDHA inhibitor, oxamate sodium, was purchased from Sigma-Aldrich (17 (link)).

Cui J., Shi M., Xie D., Wei D., Jia Z., Zheng S., Gao Y., Huang S, & Xie K. (2014). FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression via Transactivation of LDHA Expression. Clinical cancer research : an official journal of the American Association for Cancer Research, 20(10), 2595-2606.

+ Open protocol

+ Expand

Pancreatic Cancer Organoid Development

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human pancreatic cancer cell line, AsPC-1, was cultured in RPMI with 10% fetal bovine serum (FBS), 1% L- Glutamine, and 1% penicillin streptomycin(P/S). Panc-1 was cultured in DMEM with 10% FBS and 1% P/S. Both AsPC-1 and Panc-1 were purchased from ATCC.
Pancreatic tumors from patients with pancreatic ductal adenocarcinoma were collected under IRB12-1108 and IRB13-1149, confirmed to be tumor based on pathologic assessment, and developed into organoid culture according to established protocols (Romero-Calvo et al., 2019 (link)). Four different organoids, U0118-8, U049MAI, U114SOK, and U123M15-T, were investigated. For the optimal culture, derived organoids were embedded in growth factor reduced Matrigel and cultured in Intesticult complete media, supplemented with A83-01, fibroblast growth factor 10, gastrin I, N-acetyl-L-cysteine, nicotinamide, and B27 supplement, primocin. Tocris Y-27632 dihydrochloride, a selective p160 ROCK inhibitor, was added when thawing the organoids (Romero-Calvo et al., 2019 (link)).

Tian Q., Zhang P., Wang Y., Si Y., Yin D., Weber C.R., Fishel M.L., Pollok K.E., Qiu B., Xiao F, & Chong A.S. (2023). A novel triptolide analog downregulates NF-κB and induces mitochondrial apoptosis pathways in human pancreatic cancer. eLife, 12, e85862.

+ Open protocol

+ Expand

Evaluating Pancreatic Cancer Cell Migration

Check if the same lab product or an alternative is used in the 5 most similar protocols

PC cell lines AsPC-1, PANC-1, CFPAC-1, MIA PaCa-2, BxPC-3 and normal pancreatic ductal epithelial cell line HPNE were all purchased from the ATCC (Manassas, VA, USA). All cell lines were cultured inDMEM high glucose medium containing 10% FBS (Gibco, Rockville, MD, USA), penicillin (100 U/mL) and streptomycin (100 μg/mL) in a 37°C, 5% CO₂ incubator. Detection of migrative ability was determined via Transwell assay.

Fan Z., Li M., Xu Y., Ge C, & Gu J. (2023). EPS8L3 promotes pancreatic cancer proliferation and metastasis by activating GSK3B. Journal of Medical Biochemistry, 42(1), 105-112.

+ Open protocol

+ Expand

Culturing 293T, BXPC-3, AsPC-1 and Human T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Briefly, 293T cells (cat. no. CRL-3216) were obtained from American Type Culture Collection (ATCC) and cultured with Dulbecco’s Modified Eagle’s Medium (DMEM; cat. no. 11995-065; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (FBS; cat. no. 10099-141; Gibco; Thermo Fisher Scientific, Inc.). BXPC-3 (CRL-1687, ATCC) and AsPC-1 (CRL-1682, ATCC) cells were obtained from ATCC and cultured in RPMI-1640 medium (cat. no. 11875093; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS. Human T cells were obtained from Allcells (cat. no. PB009-CD3-F). Both of the cells were cultured in 5% CO₂ at 37°C.

Hu J.F., Wang Z.W., Liao C.Y., Chen Z.W., Kang F.P., Lin C.F., Lin T.S., Huang L., Tian Y.F, & Chen S. (2022). Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability. Frontiers in Immunology, 13, 958960.

+ Open protocol

+ Expand

Characterization of Pancreatic Cancer Cell Lines

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human pancreatic cancer cell lines AsPC1 (CRL-1682), BxPC3 (CRL-1687), CFPAC1 (CRL-1918), MIAPaCa2 (CRL-1420), PANC1 (CRL-1469), and BJ fibroblasts (CRL-2522) were acquired from ATCC, KP4 (JCRB0182) from JCRB, and cultured per supplier’s instructions. HPDE6C7 was provided by Tsao group (U. Toronto) and cultured as previously described^{31 (link)}. The spontaneously immortalized human pancreatic stellate cell line hPSC, ONO, and YAM1 were kindly provided by the Evans group (Salk) as previously described^{11 (link)}. Normal human fibroblast cells were a kind gift from the Gage group (Salk). MEF cells for Lifr gene knockout characterization were isolated from individual embryos at E13.5, and cultured in DMEM containing 10% FBS for less than five passages. For the low dosage Gem treatment assay, 3 nM gemcitabine or vehicle (PBS) were used.

Shi Y., Gao W., Lytle N.K., Huang P., Yuan X., Dann A.M., Ridinger-Saison M., DelGiorno K.E., Antal C.E., Liang G., Atkins A.R., Erikson G., Sun H., Meisenhelder J., Terenziani E., Woo G., Fang L., Santisakultarm T.P., Manor U., Xu R., Becerra C.R., Borazanci E., Von Hoff D.D., Grandgenett P.M., Hollingsworth M.A., Leblanc M., Umetsu S.E., Collisson E.A., Scadeng M., Lowy A.M., Donahue T.R., Reya T., Downes M., Evans R.M., Wahl G.M., Pawson T., Tian R, & Hunter T. (2019). Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature, 569(7754), 131-135.

+ Open protocol

+ Expand

Characterization of Pancreatic Cancer Cell Lines

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The pancreatic cancer cell lines AsPC-1, Capan-1, HPAF-II, MIA PaCa-2, and PANC-1 were received from ATCC (Manassas, VA). These cell lines were propagated, expanded, and frozen immediately upon receipt. The cells revived from the frozen stock were used within 10-20 passages, not exceeding a period of 2-3 months. The ATCC uses morphological, cytogenetic, and DNA profile analyses for characterization of cell lines. Human pancreatic ductal epithelial (HPDE) cells were kindly received from Dr. Ming Tsao of the Ontario Cancer Institute (Toronto, Canada). The L3.6pl cell line was kindly received from Dr. Isiah D. Fidler at The University of Texas MD Anderson Cancer Center (Houston, TX). Both HPDE and L3.6pl cell lines were handled as other cell lines and were genotyped by DNA fingerprinting (PowerPlex 16; Promega, Madison, WI) as per the manufacturer’s instructions. The growth conditions of all cell lines were performed as described previously [36 (link)].

Mody H.R., Hung S.W., Naidu K., Lee H., Gilbert C.A., Hoang T.T., Pathak R.K., Manoharan R., Muruganandan S, & Govindarajan R. (2017). SET contributes to the epithelial-mesenchymal transition of pancreatic cancer. Oncotarget, 8(40), 67966-67979.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!